{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:03:18Z","timestamp":1789768998021,"version":"4.0.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Human cytomegalovirus (HCMV) remains a major cause of morbidity and mortality in immunocompromised individuals and newborns worldwide. Current antiviral therapies mainly target the viral DNA polymerase, but their long-term clinical use is often constrained by toxicity and the emergence of drug-resistant strains. The approval of letermovir, the first antiviral targeting the viral terminase complex, has established viral genome packaging as a highly effective therapeutic strategy. The HCMV terminase complex is essential for viral DNA cleavage and encapsidation and lacks direct human homologs, making it an attractive target for selective antiviral intervention. Accumulating evidence indicates that letermovir may primarily target pUL56, as resistance mutations cluster predominantly within this subunit. This review summarizes current understanding of the interaction between letermovir and the HCMV terminase, focusing on structural organization, inhibitory mechanisms, resistance mutations, and emerging approaches for next-generation inhibitor development, and highlighting key unresolved questions that will guide future structure-based antiviral discovery targeting herpesvirus genome packaging machinery.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1942629","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:35:43Z","timestamp":1789767343000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The HCMV terminase as an antiviral target: structural insights, inhibitory mechanisms, and the era of letermovir"],"prefix":"10.3389","volume":"17","author":[{"given":"Guojun","family":"Chen","sequence":"first","affiliation":[{"name":"Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]},{"name":"School of Pharmacy, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Li","sequence":"additional","affiliation":[{"name":"Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]},{"name":"School of Pharmacy, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Chen","sequence":"additional","affiliation":[{"name":"Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]},{"name":"School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangqing","family":"Dong","sequence":"additional","affiliation":[{"name":"Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]},{"name":"School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan","place":["Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e70768","DOI":"10.1002\/jmv.70768","article-title":"Unraveling cytomegalovirus drug resistance in transplant patients by targeting deep sequencing","volume":"98","author":"Alem\u00e1n","year":"2026","journal-title":"J. Med. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.str.2022.11.014","article-title":"Frozen in time: analyzing molecular dynamics with time-resolved cryo-EM","volume":"31","author":"Amann","year":"2023","journal-title":"Structure"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e08006","DOI":"10.1002\/advs.202508006","article-title":"Discovery of a baloxavir-inspired endonuclease inhibitor that prevents herpes simplex virus 1 replication in cell culture and in vivo","volume":"12","author":"Andreu","year":"2025","journal-title":"Adv. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1134\/S0012496624701035","article-title":"Combined effect of basic antiherpetic drugs with a new inhibitor of the terminase complex of herpes simplex virus type 1 in vero cell cultures","volume":"517","author":"Andronova","year":"2024","journal-title":"Dokl. Biol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/v13030474","article-title":"Small molecules\u2014prospective novel HCMV inhibitors","volume":"13","author":"Bogner","year":"2021","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1128\/JVI.72.3.2259-2264.1998","article-title":"The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity","volume":"72","author":"Bogner","year":"1998","journal-title":"J. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1021\/acsomega.8b01472","article-title":"Structure-driven discovery of \u03b1,\u03b3-diketoacid inhibitors against UL89 herpesvirus terminase","volume":"3","author":"Bongarzone","year":"2018","journal-title":"ACS Omega"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0019122","DOI":"10.1128\/spectrum.00191-22","article-title":"Assessment of UL56 mutations before letermovir therapy in refractory cytomegalovirus transplant recipients","volume":"10","author":"Bravo","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106237","DOI":"10.1016\/j.antiviral.2025.106237","article-title":"Generation of a panel of mutants that are resistant to standard of care therapies in a clinically relevant strain of human cytomegalovirus for drug resistance profiling","volume":"241","author":"Carter","year":"2025","journal-title":"Antiviral Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2406138121","DOI":"10.1073\/pnas.2406138121","article-title":"Structural basis for DNA recognition by a viral genome-packaging machine","volume":"121","author":"Chechik","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1021\/acsinfecdis.6b00079","article-title":"A small covalent allosteric inhibitor of human cytomegalovirus DNA polymerase subunit interactions","volume":"3","author":"Chen","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"","journal-title":"Antiviral Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e01325","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105422","DOI":"10.1016\/j.antiviral.2022.105422","article-title":"Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing","volume":"207","author":"Chou","year":"2022","journal-title":"Antiviral Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.vetmic.2017.12.016","article-title":"Broad anti-herpesviral activity of \u03b1-hydroxytropolones","volume":"214","author":"Dehghanpir","year":"2018","journal-title":"Vet. Microbiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole- d -ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.semperi.2018.02.002","article-title":"Congenital cytomegalovirus infection","volume":"42","author":"Fowler","year":"2018","journal-title":"Semin. Perinatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1021\/bi5003234","article-title":"Broad-spectrum allosteric inhibition of herpesvirus proteases","volume":"53","author":"Gable","year":"2014","journal-title":"Biochemistry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"106289","DOI":"10.1016\/j.antiviral.2025.106289","article-title":"Deciphering letermovir's mode of action and resistance mutation effects","volume":"244","author":"Gourin","year":"","journal-title":"Antiviral Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"44943","DOI":"10.1038\/s41598-025-28915-5","article-title":"Key domains involved in the interaction and assembly of the HCMV terminase complex","volume":"15","author":"Gourin","year":"","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/tropicalmed9020049","article-title":"Human cytomegalovirus (HCMV) genetic diversity, drug resistance testing and prevalence of the resistance mutations: a literature review","volume":"9","author":"Grgic","year":"2024","journal-title":"Trop. Med. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/10600280241237534","article-title":"Cytomegalovirus treatment in solid organ transplantation: an update on current approaches","volume":"58","author":"Hardinger","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1021\/acs.jmedchem.2c00203","article-title":"4,5-Dihydroxypyrimidine methyl carboxylates, carboxylic acids, and carboxamides as inhibitors of human cytomegalovirus pUL89 endonuclease","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1074\/jbc.M108984200","article-title":"ATPase activity of the terminase subunit pUL56 of human cytomegalovirus","volume":"277","author":"Hwang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1248\/bpb.b23-00717","article-title":"The terminase complex of each human herpesvirus","volume":"47","author":"Iwaisako","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"B33","doi-asserted-by":"publisher","first-page":"13874","DOI":"10.1021\/acs.jmedchem.3c01280","article-title":"Inhibiting HCMV pUL89-C endonuclease with metal-binding compounds","volume":"66","author":"Jagtap","year":"2023","journal-title":"J. Med. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/molecules30163402","article-title":"PROTACs in antivirals: current advancements and future perspectives","volume":"30","author":"Jin","year":"2025","journal-title":"Molecules"},{"key":"B35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10334","DOI":"10.1038\/s41598-025-94809-1","article-title":"Identification of a binding pocket of letermovir in the terminase subunit pUL56 of human cytomegalovirus","volume":"15","author":"Kmetsch","year":"2025","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1972","DOI":"10.1002\/rmv.1972","article-title":"Human herpesvirus portal proteins: structure, function, and antiviral prospects","volume":"28","author":"Kornfeind","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41390-023-02957-9","article-title":"Decoding human cytomegalovirus for the development of innovative diagnostics to detect congenital infection","volume":"95","author":"Lawrence","year":"2024","journal-title":"Pediatr. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s13238-020-00716-8","article-title":"Progress towards revealing the mechanism of herpesvirus capsid maturation and genome packaging","volume":"11","author":"Li","year":"2020","journal-title":"Protein Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/v11121093","article-title":"Highlighting of a LAGLIDADG and a zing finger motifs located in the pUL56 sequence crucial for HCMV replication","volume":"11","author":"Ligat","year":"2019","journal-title":"Viruses"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1038\/s41598-017-09469-7","article-title":"Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit","volume":"7","author":"Ligat","year":"2017","journal-title":"Sci. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs. valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"106259","DOI":"10.1016\/j.antiviral.2025.106259","article-title":"First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex","volume":"242","author":"Mafi","year":"2025","journal-title":"Antiviral Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/rmv.558","article-title":"Human cytomegalovirus DNA replication: antiviral targets and drugs","volume":"18","author":"Mercorelli","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the national vaccine advisory committee","volume":"39","author":"Modlin","year":"2004","journal-title":"Clin Infect Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/QCO.0000000000000983","article-title":"A new direction for cytomegalovirus prophylaxis among transplant recipients: benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis","volume":"36","author":"Moore","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"105361","DOI":"10.1016\/j.antiviral.2022.105361","article-title":"First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure","volume":"204","author":"Muller","year":"2022","journal-title":"Antiviral Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1073\/pnas.1007144107","article-title":"Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain","volume":"107","author":"Nadal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e02384","DOI":"10.1128\/JVI.02384-16","article-title":"Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation","volume":"91","author":"Neuber","year":"2017","journal-title":"J. Virol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1099\/jgv.0.000984","article-title":"The C-terminal part of the human cytomegalovirus terminase subunit pUL51 is central for terminase complex assembly","volume":"99","author":"Neuber","year":"2018","journal-title":"J. Gen. Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O'Brien","year":"2018","journal-title":"Antiviral Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"106446","DOI":"10.1016\/j.antiviral.2026.106446","article-title":"Human cytomegalovirus terminase inhibitors letermovir, tomeglovir, and the halogenated benzimidazoles modify DNA cleavage\/packaging to generate a super-genomic DNA species by cleavage site skipping","volume":"251","author":"Ourahmane","year":"2026","journal-title":"Antiviral Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ddc4030042","article-title":"Design of a first-in-class homoPROTAC to induce ICP0 degradation in human herpes simplex virus 1","volume":"4","author":"Salimova","year":"2025","journal-title":"Drugs Drug Candidates"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","article-title":"The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure","volume":"30","author":"Scheffczik","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/nar\/gkg229","article-title":"Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus","volume":"31","author":"Scholz","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-025-08766-w","article-title":"Structural dynamics of DNA unwinding by a replicative helicase","volume":"641","author":"Shahid","year":"2025","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s43556-024-00226-7","article-title":"Human cytomegalovirus: pathogenesis, prevention, and treatment","volume":"5","author":"Shang","year":"2024","journal-title":"Mol. Biomed."},{"key":"B63","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/biom9100603","article-title":"Hinge region in DNA packaging terminase pUL15 of herpes simplex virus: a potential allosteric target for antiviral drugs","volume":"9","author":"Thaljeh","year":"2019","journal-title":"Biomolecules"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e1008175","DOI":"10.1371\/journal.ppat.1008175","article-title":"Full-length human cytomegalovirus terminase pUL89 adopts a two-domain structure specific for DNA packaging","volume":"15","author":"Thei\u00df","year":"2019","journal-title":"PLoS Pathog."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1021\/bi0600796","article-title":"Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus","volume":"45","author":"Thoma","year":"2006","journal-title":"Biochemistry"},{"key":"B66","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12879-026-13022-1","article-title":"Beyond valganciclovir: a meta-analysis of letermovir's safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantation","volume":"26","author":"Usman","year":"2026","journal-title":"BMC Infect. Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/1743-422X-9-315","article-title":"Changes in subcellular localization reveal interactions between human cytomegalovirus terminase subunits","volume":"9","author":"Wang","year":"2012","journal-title":"Virol. J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e02152","DOI":"10.1128\/JVI.02152-16","article-title":"Inhibition of human cytomegalovirus pUL89 terminase subunit blocks virus replication and genome cleavage","volume":"91","author":"Wang","year":"2017","journal-title":"J. Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-hiv compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1636978","DOI":"10.3389\/fimmu.2025.1636978","article-title":"Recent advances in human cytomegalovirus: a comprehensive review of pathogenic mechanisms, virus-host interactions, and antiviral strategies","volume":"16","author":"Xia","year":"2026","journal-title":"Front. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"117044","DOI":"10.1016\/j.celrep.2026.117044","article-title":"Structural basis for rep-mediated adeno-associated virus packaging","volume":"45","author":"Xu","year":"2026","journal-title":"Cell Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s13238-020-00710-0","article-title":"Architecture of the herpesvirus genome-packaging complex and implications for DNA translocation","volume":"11","author":"Yang","year":"2020","journal-title":"Protein Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"8440","DOI":"10.1038\/s41467-026-75257-5","article-title":"Structural dynamics of RNA polymerase II throughout the nucleotide addition cycle","volume":"17","author":"Yi","year":"2026","journal-title":"Nat. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.virusres.2017.01.019","article-title":"Herpesvirus DNA polymerases: structures, functions and inhibitors","volume":"234","author":"Zarrouk","year":"2017","journal-title":"Virus Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"108437","DOI":"10.1016\/j.bioorg.2025.108437","article-title":"Recent advances in PROTAC-based antiviral and antibacterial therapeutics","volume":"160","author":"Zhou","year":"2025","journal-title":"Bioorg. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"118208","DOI":"10.1016\/j.ejmech.2025.118208","article-title":"Antiviral strategies based on targeted protein degradation: an overview of the literature and future outlook","volume":"301","author":"Zhou","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/QCO.0000000000001065","article-title":"The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies","volume":"37","author":"Zhu","year":"2024","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1942629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:35:45Z","timestamp":1789767345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1942629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":77,"alternative-id":["10.3389\/fmicb.2026.1942629"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1942629","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1942629"}}